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ABSTRACT With the launch of the Precision Medicine Initiative (PMI) in Jan-
uary 2015, the White House granted a high degree of federal support to an emerging 
biomedical paradigm. What explains this level of political recognition? Based on lit-
erature and policy analysis, we reconstruct the scientific and the legislative paths that 
led to the political endorsement of precision medicine. First, we describe the prolifer-
ation of personalized approaches to therapy ignited by the discovery of hemoprotein 
cytochrome P450 polymorphism in 1988. Then, we analyze the legislative history of 
precision medicine, from the unsuccessful introduction of Genomics and Personalized 
Medicine Acts in the second half of the last decade, to the highly acclaimed PMI. How-
ever, scientific progress and political contingency alone do not explain the upheaval 
of precision medicine as an institutionally supported initiative. On examination, the 
launch of a Precision Medicine Research Cohort and the incorporation of a participa-
tory ethos into the fabric of the PMI proved to be crucial determinants of the political 
support for precision medicine. Weaving together the scientific and legislative anteced-
ents of precision medicine, we illuminate how the mutual constitution of science and 
social order generates political recognition for innovative biomedical paradigms.
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Some patients tolerate a given drug well, without adverse reactions. For oth-ers, though, an identical dose of the same medication can have toxic effects. 
Moreover, while a drug can be effective at relieving symptoms for some patients, 
it may fail to do the same for others suffering with the same disease. With such 
variability in treatment responses, tailoring medical interventions to individual 
patients has long been an aspiration of medicine. Until recently, however, medi-
cine lacked a clear understanding of the biological reasons for human variation in 
drug response. Attempting to adjust treatment to the individual patient, physicians 
have relied primarily on direct observation, trial-and-error, and, ultimately, on 
their own clinical judgment.
In the late 1980s, analyses of the genetic bases of individual variation in drug 
response propelled unprecedented scientific interest in the prospects of develop-
ing more accurate, patient-tailored preventive, diagnostic, and therapeutic inter-
ventions. During the next two decades, the label “personalized medicine” was 
used to designate a bundle of emerging approaches based on technological and 
scientific advancements in fields such as genetics, genomics, bioinformatics, and 
targeted pharmacology. The promoters of personalized medicine have described 
these approaches as a novel medical project aimed at providing “each patient with 
the right drug at the right dose at the right time” (Hamburg and Collins 2010). To 
be sure, some commentators have been skeptical of the assertion that the concept 
of personalized medicine is something new (Steele 2009). Nevertheless, promises 
of an imminent clinical revolution have driven considerable interest. Recently, 
the promise of personalized health care has acquired strong political support, most 
notably evidenced by the launch of the Precision Medicine Initiative (PMI) by 
President Barack Obama in January 2015, and its associated national research 
cohort comprised of 1 million Americans and run by the National Institutes of 
Health (NIH).
Precision medicine is the latest branding of a family of approaches—includ-
ing pharmacogenetics, pharmacogenomics, P4 medicine, and personalized medi-
cine—all aimed at tailoring therapy to patients. The first clinical successes in this 
area date back to the late 1990s, with the development of the first targeted ther-
apies, such as Herceptin for HER2-positive breast cancer, approved by the Food 
and Drug Administration (FDA) in 1998. It is notable, however, that it took an-
other 20 years after these success stories for personalized medicine to be endorsed 
politically. Our aim is not to assess whether that support is warranted, let alone 
to promote the claim that precision medicine will bring about a major shift in 
medical research and clinical care. Rather, we aim to examine the organizational 
and ethical elements that were mobilized to win political support for precision 
medicine after a series of failed attempts.
To explain the political uptake of precision medicine, we reviewed both its sci-
entific and political antecedents. In particular, we reconstructed the basic features 
of four approaches developed after the discovery of hemoprotein cytochrome 
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P450 polymorphism in 1988, a scientific milestone in the understanding of hu-
man variability in drug metabolism: pharmacogenetics, pharmacogenomics, per-
sonalized medicine and P4 medicine (see Table 1). We drew from the most cited 
papers describing each of these approaches as the basis for our content analysis.1 
We then compared the results of this analysis with how personalized medicine 
is described and imagined in political discourse. To this aim, we examined four 
legislative acts that were unsuccessfully introduced in the Congress of the United 
States between 2006 and 2010 and intended to ensure support for genomics and 
personalized medicine. Finally, we compared the imagined features of personal-
ized medicine in those policy documents with the present framing of the White 
House Precision Medicine Initiative (PMI).2 Through this process, we were able 
to trace the emergence of novel elements in the framing of personalized medicine 
that made this iteration politically more palatable.
Genes, Drugs, and the Puzzle of Individual  
Variation
Individual variability in response to drugs has long been a vexing issue in medi-
cine and pharmacology. However, the realization that this issue could be illumi-
nated in terms of genetics, dates back only to the late 1950s, when Fredrich Vogel 
introduced the term pharmacogenetics to designate a branch of medicine focused on 
identifying the genetic determinants of variation in drug response (Jones 2013).
This new field did not generate much clinical interest until the 1980s, when 
allelic variation in cytochrome P450 (a major genetic locus encoding for multiple 
variants of crucial receptors for drug metabolism) started to be extensively char-
acterized (Gonzalez 1988). Following this discovery, multiple research efforts in 
both the public and private sectors explored the possibility of tailoring treatments 
to the specificities of each patient.
The term pharmacogenetics gained traction in the early 1990s, as the relationship 
among genes, drugs, and disease outcomes attracted increasing scientific attention. 
Pharmacogentics generally refers to two distinct but interrelated endeavors: clari-
fying the genetic bases of variability in adverse drug reactions and drug response, 
and understanding the genetic components of human disease in order to isolate 
novel pharmacological targets (Meyer 2000; Roses 2000, 2004). The first strand of 
1For each paradigm we have searched the Web of Science for papers featuring the name of the paradigm 
in the title field. (For P4 medicine we had to query “P4” AND “medicine,” and we also queried “P4 
medicine” in the topic field and generated a list with the first 10 items for number of citations from 
each search.) The period was 1988–2016. Our inclusion criteria were as follows: only papers in English 
appearing in the first 50 hits of the list (from most to less cited); only unspecific papers (with no men-
tion of specific genetic loci or disease in the title—but papers with only “cancer” were retained); and at 
least one citation. We retained the first 10 unspecific papers (from most to less cited); irrelevant papers 
were cleaned up manually.
2For our analysis of the PMI, we have used the following sources: PMI Working Group 2015; White 
House 2015a, 2015b, 2015c, 2016.
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Table 1  publication trends for pharmacogenetics, pharmacogenomics, and  
personalized medicine
Period               Pharmacogenetics     Pharmacogenomics       Personalized               All medical  
                                                                                       medicine                    articles*
2001–2005 837 (0.15%) 724 (0.13%) 202 (0.03%) 532,348 
2006–2010 1,358 (0.19%) 1,098 (0.15%) 1,249 (0.17%) 708,900 [1.3]
2011–2015 1,918 (0.16%) 1,680 (0.14%) 4,764 (0.41%) 1,154,041 [1.6]
*Absolute numbers obtained by querying for the word medical in any field in each time period. Numbers in 
square brackets represent the fold change increase with respect to the previous period. 
          
Data show the number of PubMed publications featuring the words pharmacogenetics, pharmacogenomics, and 
personalized medicine (or personalised medicine) in either title or abstract. We report absolute numbers for each 
period and, in brackets, the percentage these numbers represent of the overall number of medical articles in 
the same period. Publication trends show that “personalized medicine” enjoyed a more rapid growth (from 
0.17% to 0.41% of all published medical articles) than the two other paradigms between 2011 and 2015. 
Between 2001 and 2015, a total of 46 publications mention “P4 medicine” in their title or abstract (data not 
included in the table).
pharmacogenetics offered insight into the genetics behind variability in pharma-
cokinetics and pharmacodynamics, and thus promised to lead to improved drug 
safety and efficacy (Meyer 2000). The second strand, instead, aimed at developing 
more effective drugs based on the identification of previously unknown molecu-
lar targets. In both cases, however, emphasis is on making and administering drugs 
that are tailored to the individual genetic features of patients, thus pushing med-
icine towards a more personalized approach. The language of personalization is 
already present in some influential publications of this early period (Roses 2000), 
but at the turn of the century, the term pharmacogenetics was much more common-
ly used than “personalized medicine.”
More specifically, in the case of drug response, the discovery of genetic factors 
influencing how a patient metabolizes a given drug led to the realization that pa-
tients can be stratified according to their genotype and assigned to genotype-spe-
cific pharmacological regimes (Gardiner and Begg 2006; Meyer 2000; Roses 
2004). This conceptual shift played out even more prominently in the develop-
ment of drugs targeted to the varying genetic characteristics of human diseases.3 
Novel disease taxonomies were created, as previously unified conditions were 
specified as sub-diseases, each bearing distinct genetic characteristics. Following 
this strategy of stratification (rather than a language of personalization), scientists 
and companies working in pharmacogenetics were directed their efforts towards 
developing small molecules capable of modifying a growing number of new tar-
3In PubMed publications, the term stratification does not appear in association with “drug response” 
before 1999 (in titles and abstracts). This indicates that the concept of stratification in pharmacology 
represents a novelty in this field.
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gets. With this reclassification, patients wound up in smaller disease-groups, re-
ceiving more tailored and, ideally, more effective drugs that matched the precise 
genetic features of their own diseases. In breast cancer, for example, the realization 
that a sub-group of patients overexpresses a specific protein (HER2) led to the 
development of trastuzumab, a monoclonal antibody eventually approved by the 
FDA in 1998 with the commercial name Herceptin. This approval is generally 
considered a topical success story for pharmacogenetics. Moreover, other drugs 
approved around the same years count as success stories for the second strand of 
pharmacogenetics, focused on targeting specifically defined components of mo-
lecular pathways involved in disease onset and progression. Prominent examples 
include imatinib for chronic myeloid leukemia, approved in 2001 as Gleevec, 
which was later extended to treat gastrointestinal stromal tumors (where it blocks 
the c-Kit cascade).
A Genomic Turn
In 2000, the prospects of pharmacogenetics were galvanized by the comple-
tion of the Human Genome Project (HGP), and then the first draft of the entire 
sequence of human DNA. Soon after came rapid progress in the development of 
faster and cheaper sequencing technologies, gradually leading to the introduction 
of variants for the word pharmacogenetics, terms such as “pharmacogenomics” and 
“genomic medicine.” Obviously, the advantage of genome sequencing compared 
to more traditional genotyping at specific loci is its ability to capture a wider array 
of variations, including not only naturally occurring polymorphism and acquired 
mutations at the level of DNA, but also differences in gene expression that can 
affect drug metabolism and entire disease-altered molecular pathways (Evans and 
Relling 1999, 2004).
Genomics, then, promises to identify a spectrum of disease-related alterations 
as targets for new drugs. Moreover, with pharmacogenomics, the identification 
of clinically relevant biomarkers (that is, biological markers, like cell surface re-
ceptors, or genetic markers, such as single nucleotides polymorphisms) nurtured 
the expectation that more individualized treatments could soon be discovered.4 
The value of pharmacogenomic biomarkers lies in their ability to inform ther-
apeutic decisions by predicting mechanisms of action, clinical response, adverse 
side effects, and genotype-specific dosing for patients carrying the biomarker. 
Currently, the list of FDA-approved drugs having a pharmacogenomic biomarker 
information in their label includes 163 drugs, signaling a substantial translational 
output (FDA 2016).
4The NIH Biomarkers Definition Working Group (2001) specifies that the word biomarker should be 
used to designate “A characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”  
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Towards Personalized Medicine
Around 2005, the term “personalized medicine” started enjoying widespread 
circulation. Generally, it designates health care “informed by each person’s unique 
clinical, genetic, genomic, and environmental information” (Ginsburg and Wil-
lard 2009). The actual implementation of personalized medicine thus depends 
on the convergence of both data and expertise from different disciplinary am-
bits. Nevertheless, genomic data and biomarkers feature as focal epistemic drivers 
in most definitions of personalized medicine (Whirl-Carrillo et al. 2012). Most 
importantly, this paradigm promotes a comprehensive approach to health care, 
spanning health monitoring, disease prevention, health promotion, and clinical 
care. Also interestingly, personalized medicine is often associated with a narrative 
of optimization of diagnostic and therapeutic interventions and the customization 
of patient care.
Popularized by the idea of “steering the patient to the right drug at the right 
dose at the right time” (Hamburg and Collins 2010), personalized medicine soon 
appeared to be more aspirational than originally believed. In a much cited Per-
spectives piece in the New England Journal of Medicine, the leadership of the NIH 
and the FDA emphasized that, despite advances in knowledge and technology, 
personalized medicine would not materialize on its own without dedicated or-
ganizational input. Advances in basic science, translational science, and regulatory 
science, the authors stressed, must occur to create the conditions for personalized 
medicine to develop (Hamburg and Collins 2010). Other influential papers also 
highlight impediments—both scientific and regulatory—to the effective transla-
tion of knowledge into personalized clinical applications, insisting that expected 
advances may not be right around the corner (Chin, Andersen, and Futreal 2011; 
Ginsburg and McCarthy 2001; Ginsburg and Willard 2009). Even so, success sto-
ries in patient-tailored therapy kept the hope alive for a bright future for person-
alized medicine.
During this same time, the availability of comprehensive data sets prompted in-
terest in a systems-level understanding of biology (Weston and Hood 2004). This 
approach is based on the elucidation of genetic networks (including both gene-
gene and gene-protein interaction) and biochemical pathways, now enabled by 
rapidly accruing genomic data. By modeling the systemic properties of biological 
phenomena, this field of inquiry holds promise of fully exploiting information 
gained in genome sequencing. Systems biology aims to understand what ensures 
the robustness, or the homeostatic stability, of a given biological phenomenon 
and what, on the flip side, leads to its pathological perturbation. The emerging 
model of system biology gained widespread recognition by the mid-2000s as 
an approach that, integrating “wet” experimental data and “dry” computational 
methods, could find relevant application in clinical medicine (Kitano 2002). In 
particular, identifying disease-perturbed networks in individual patients came to 
be seen as a proxy for more personalized therapeutic and preventive strategies 
(Flores et al. 2013).
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Interestingly, among the most-cited papers developing the concept of person-
alized medicine, this model for personalized medicine is often woven together 
with that of systems biology (Nicholson 2006; Weston and Hood 2004), each 
concept leaning on the other for its own articulation.
P4 Medicine: Patients as Partners in Research
A 2011 paper by Leroy Hood and Stephen Friend introduced the notion of P4 
medicine. P4 medicine served as a placeholder for what was to become a more 
comprehensive approach based on four pillars: prediction, prevention, personaliza-
tion, and participation. This model focused attention on the emerging conjugation 
of genomics, computation, and clinical practice. Although the P4 model does 
not figure largely in major policy initiatives—such as the Stratified Medicine 
Programme in the United Kingdom (2013) and the PMI in the United States 
(2015)—it played an important role in the subsequent broadened articulation 
of personalized medicine. Hood and colleagues argued for an already ongoing 
transformative shift in medicine, from treating disease in a reactive fashion to 
maximizing well-being in a proactive way.
This shift is understood as both a technical and a societal revolution. To accom-
plish the shift, it is argued, medicine should rely on a variety of data, including 
not only genetic, but also epigenetic, transcriptomic, proteomic, and metabolomic 
data, as well phenotypic measurements of all sorts. Such comprehensive data sets 
would enable the construction of predictive models measuring individual base-
line wellness, and thus able to predict transition to disease. Combined with ef-
forts aimed at the stratification of diseases into increasingly precise subtypes, these 
models are supposed to lead to the personalization of treatment to the individual 
characteristics of each patient. The third pillar of P4 medicine, prevention, refers to 
the ability to target “disease-perturbed molecular networks [in order] to deter or 
stop disease progression” (Hood and Friend 2011). The fourth pillar of the model, 
participation, has more to do with the societal implementation of the others. In this 
area, the authors propose moving beyond the current model of clinical trial par-
ticipation and embracing what they call “citizen-driven trials,” in which patients 
become partners of science on the road to personalized medicine. In this model, 
research takes place by directly crowd-sourcing patients who have an interest 
in participating, as opposed to conventional enrollment methods. The rationale 
for distributed, crowd-sourced trial networks stems from the need to pull data 
from cohorts much larger than those accessible though a clinical trial, enabling 
researchers to uncover sets of molecular alterations that can drive clinical strati-
fication. An obvious corollary to this public engagement turn is the willingness 
of participants to share samples, biological data, phenotypic measurements, and 
medical health records, possibly in a much more extensive way than is currently 
allowed under the Common Rule. However, the generation and collection of 
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such extensive amounts of data, the authors noted, raises major ethical issues with 
respect to privacy, data security, and ownership.
Despite the fact that its characteristic emphasis on systems medicine has not 
become mainstream in current articulations of precision medicine, the P4 model 
has crystallized the link between personalized approaches to medicine and the 
ethos of participation. This feature is still central to what is now called precision 
medicine.
Personalized Medicine Struggling for  
Political Support
In the first decade of the new century, while scientific circles elaborated and re-
fined the very idea of personalized medicine, politicians turned toward it as well. 
In particular, in 2006, then-Senator Barack Obama (D-IL), introduced a Genom-
ics and Personalized Medicine Act intended to provide institutional support to the 
development of this field (S.3822).
The 2006 Act was the first of a series of four legislative initiatives bearing the 
same name and all aimed at fostering the promise of improving the accuracy of 
prevention, diagnosis and treatment. The other three were introduced in 2007 
(S.976, again by Sen. Barack Obama, with support of Sen. Richard Burr, R-NC), 
in 2008 (H.R. 6498, by Congressman Patrick Kennedy, D-RI) and in 2010 (H.R. 
5440, again by Kennedy and Congresswoman Anna Eshoo, D-CA), respectively. 
Despite growing expectations surrounding personalized medicine, however, none 
of these bills eventually passed into law. Examining them is nonetheless crucial for 
understanding how this field struggled to secure institutional endorsement, and 
what it took to eventually win that support in 2015.
Genomics and Personalized Medicine Acts
The first three versions of the Genomics and Personalized Medicine Act (2006, 
2007 and 2008) share a similar definition of personalized medicine, intended as 
“the application of genomic and molecular data to better target the delivery of 
health care, facilitate the discovery and clinical testing of new products, and help 
determine a patient’s predisposition to a particular disease or condition.” They also 
identify specific institutional needs that must be met in order to ensure person-
alized medicine fulfills its promise, including the need for federal leadership, the 
need to accelerate the rate of discovery, and incentives to data collection.
In terms of political coordination, those acts propose the creation of an Inter-
agency Working Group within the Department for Health and Human Services 
(DHHS), charged with the aim of expanding and accelerating research and clin-
ical translation by enhancing coordination and communication among Federal 
departments and agencies (sec. 4(1)(A)).
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The main stimulus to the growth of personalized medicine envisioned by those 
acts is the creation of the infrastructure that will accelerate the development of 
the field: a National Biobanking Distributed Database (NBDD) and Biobank Ini-
tiatives Grants (BIGs). NBDD is a system for the integration of sparse data to fa-
cilitate pooled analysis. BIGs, instead, serve the aim of fostering the establishment 
of biobanks throughout the country with the aim of advancing the application 
of genomics.
From an organizational perspective, in those acts research in personalized med-
icine relies on a distributed rather than a centralized model, leveraging resources 
from a variety of institutions disseminated across the country. Moreover, com-
prehensive and interoperable datasets constitute the central material asset for the 
further development of the field. Interestingly, as we have seen above, these two 
features would later be emphasized in the so-called P4 medicine model—thus 
signaling a two-way interaction between the political and the scientific discourse 
on personalized medicine.
Given the unsuccessful political fate of the first three acts, the fourth attempt, 
in 2010, had a substantively different framing. The very definition of the field 
appeared to be more comprehensive, now emphasizing “genes, environments and 
lifestyles” (emphasis added) as causally relevant factors of health, disease and prog-
nosis.
In the new text, the main organizational change is the proposal to grant polit-
ical coordination for the development of personalized medicine to an Office of 
Personalized Healthcare (OPH), within the office of the Secretary of the DHHS. 
The OPH, along with elaborating a long-term strategy of support for personal-
ized medicine, is charged with the identification of the impediments to the trans-
lation of scientific discoveries into concrete clinical outputs, including obstacles 
related to unsuitable regulatory constraints.
The novelty of the infrastructure is its adoption of a centralized model. In par-
ticular, the act proposes the creation of a National Biobank under the aegis of the 
NIH that should be established to advance the field of genomics and personalized 
medicine. Grants for the promotion of local biobanking initiatives, however, are 
still present in the bill. This ambiguity as to whether to adopt a distributed or a 
centralized data and sample infrastructure may indicate that, at that stage, per-
sonalized medicine did not yet possess a well-defined organizational identity—a 
feature that may in part explain why this fourth attempt was also doomed to fail 
in Congress. 
And yet, for the promoters of the Genomics and Personalized Medicine Acts, 
the development of this field needed to be backed up politically. More specifically, 
to keep up with its promises, the field needed a dedicated infrastructure whose 
creation was a responsibility of the government. The stimuli envisaged at the poli-
cy level, therefore, sought to create the conditions for the emergence of personal-
ized medicine. But oscillations between a distributed and a centralized model for 
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this infrastructure reveal that, despite grandiose claims about the expected impact 
of personalized medicine, ideas were less than clear as to how the whole plan was 
supposed to actually work in practice. Creating a distributed data infrastructure 
was initially envisaged as a priority. In the Genomics and Personalized Medicine 
Acts introduced between 2006 and 2008, the government was deeply implicated 
in the creation of a distributed database, while the collection of the biological 
samples from which data would emerge was delegated to local initiatives. How-
ever, such legislative initiatives were still very much focused on genetic data more 
than anything else. In scientific circles, the distributed model would enjoy a great 
deal of consideration until the end of the decade. By 2010, however, this model 
was no longer an obligatory passage point. In this last congressional attempt to 
secure support personalized medicine, emphasis shifts from a data to a specimens 
infrastructure—with the creation of a National Biobank.
This revised strategy anticipates a central feature of PMI: the creation of a pre-
cision medicine research cohort of one million Americans. Interestingly, the idea 
that data about individuals enabling the development of personalized therapies 
should be centrally collected first appears in a 2011 publication by the National 
Research Council entitled Toward Precision Medicine: Building a Knowledge Network 
for Biomedical Research and a New Taxonomy of Disease. Contrary to the PMI nation-
al research cohort, however, the Information Commons envisioned by the report 
is a database open for consultation to a wide spectrum of research and clinical 
actors and does not constitute a central repository of tissue samples. It is worth 
recalling that this report is also the first document from within the biomedical 
community to use the term “precision medicine,”5 although the original use of 
this expression can be traced to a 2009 book about the application of disruptive 
innovation theory to healthcare (Christensen, Grossman, and Hwang 2009).
The Political Upheaval of Precision Medicine
And the goal of the Precision Medicine Initiative is to figure out how to break down 
some of the structural or institutional barriers that prevent us from making the big 
leaps over the next several years.
—President Barack Obama (White House 2016)
Against the backdrop of the historical trajectories we have identified thus far, in 
January 2015, President Obama announced the launch of a flagship plan to finally 
realize the promise of personalized therapy. In practical terms, the PMI distributes 
$215 million from the President’s budget to the NIH ($130 million), the Nation-
5The report defines the “ultimate end point” of precision medicine as that of selecting “a subset of pa-
tients, with a common biological basis for disease, who are most likely to benefit from a drug or other 
treatment” (National Research Council 2011, 37). Successful examples of precision medicine, in the 
report, refer to pharmacogenomics approaches that are able to stratify disease taxonomies, such as the 
use of crizotinib in non-small cell lung cancer (38). 
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al Cancer Institute ($70 million), the FDA ($10 million), and the Office of the 
National Coordinator for Health Information Technology ($5 million), in order 
to conduct a series of activities that should support the development of precision 
medicine. The goal of the initiative is ambitious, as it aims to “revolutionize how 
we improve health and treat disease” (White House 2015a).
Under the new banner of precision medicine, the White House designates “an 
innovative approach to disease prevention and treatment that takes into account 
individual differences in people’s genes, environments, and lifestyles” (White 
House 2015a). The scope of this definition is reminiscent of earlier articulations of 
personalized medicine, or P4 medicine. However, the idea of considering disease 
from a systems perspective—as the perturbation of a baseline level of well-be-
ing—is not incorporated in precision medicine.
The envisioned goals of PMI are the acceleration of tailored cancer treatments, 
the constitution of a voluntary research cohort, protection of participants’ privacy, 
regulatory modernization, and public-private partnership. Contrary to previous 
proposals, though, the initiative lacks a fixed center of political coordination and 
presents a more federalized structure, whereby each of the agencies involved will 
have to take care of a specific part of the project. The NIH, nonetheless, plays 
the most prominent role, both in terms of funding and in terms of the relative 
importance of its task. In particular, the NIH would immediately start assembling 
a large longitudinal research cohort comprised of at least one million individuals 
who will consent to be comprehensively characterized based on tissue samples, 
behavioral data drawn from portable devices (such as smartphones and wearable 
devices), and medical health records.
Of the aims of the cohort, some are more specifically scientific, such as devel-
oping risk estimates based on multiple data types, optimizing cancer treatments, 
identifying the determinants of safety and efficacy for commonly used drugs, 
discovering biomarkers for common diseases, and developing the use of mobile 
health technologies to predict health outcomes. Others however, are more aspi-
rational in nature and incorporate a broader societal vision. In particular, the idea 
of engaging and empowering participants with their own data to use them to 
improve their health represents a distinctive cultural feature of the whole initiative. 
Interestingly, the research participant prefigured by the PMI research cohort is 
therefore both a contributor and an end user of the data. This feature aligns with 
the anticipated diversity of the data to be extracted from the PMI cohort. Recent 
renderings of precision medicine seem to have incorporated the idea that the de-
velopment of the field is predicated upon such diversity. In particular, Hawgood 
and colleagues (2015) have argued that the integration of genomic data, micro-
biomic data, environmental exposure data, behavioral data, patients’ health records, 
and participant-contributed data—even of the most unstructured form (like post-
ings on social network or data uploaded from smartphone apps)—will bring pre-
cision medicine beyond the “inflection point” at which “dramatic change” can 
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happen. Optimistic statements of this sort show that precision medicine is still 
characterized by the same aspirations that have marked its predecessors. Even so, 
the role that research participants might play in moving beyond that inflection 
point is a novel and distinctive feature of the PMI.
The PMI research cohort is imagined to rely on two modes of recruitment: 
direct volunteering and solicited enrollment during clinical interaction. While 
the latter mode coincides with the conventional enrollment strategy for clinical 
research, the former draws on the crowd-sourcing model originally envisaged by 
Hood and Friend (2011). Reminiscent of its participatory ethos—also initially 
developed by the proponents of P4 medicine—the PMI thus explicitly sets out to 
promote a cultural as well as a scientific revolution (PMI Working Group 2015), 
capitalizing on people’s willingness “to be active partners in modern science” 
(Collins and Varmus 2015). Public engagement in the governance of the cohort is 
thus imagined to ensure that its activities respond to the expectations and values 
of those who contribute to it in the first person. The expected advantage of this 
partnership, as imagined in the PMI, consists in fostering collaboration between 
participants and researchers in the design and management of the cohort, thus en-
suring trust and sustainability for the initiative (White House 2015b). The vision 
of the PMI in this domain, though, goes beyond issues of governance. In exchange 
for their participation, volunteers will also get access to the information generat-
ed about them through their data, thus being empowered to potentially use that 
information for health purposes.6
Precision medicine, therefore, does not only embrace a general trend towards 
expanding the scope of research participation. It also seeks to promote a culture of 
personal responsibility for one’s own health, and does so by using the language of 
empowerment. But because terms like “participation” and “empowerment” carry 
positive connotations, we should be attentive the full spectrum of ethical impli-
cations—both positive and negative—that these terms might have on the public 
perception of precision medicine.
Ethical and Cultural Drivers of Biomedical  
Innovation
Our analysis has traced the presence of distinctive features in the framing of per-
sonalized medicine that eventually won political support for the program. With 
respect to previous scientific and legislative articulations of the idea of personal-
ized medicine, the PMI embraces a centralized model of development and sets 
out to create an ad hoc data and biospecimens infrastructure. Moreover, accord-
6It remains to be seen if and to what extent this model will turn out to be empowering in terms of 
tangible health outcomes. Indeed, some commentators have expressed perplexities on the overall vision 
of precision medicine in this respect. Although interesting in their own rights, those critiques cannot be 
discussed here (see Bayer and Galea 2015).
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ing to the policy documents we have analyzed, public engagement—understood 
as active participation and empowerment—is a driving value of the enterprise. 
While we should remember to be cautious about the commendatory connotation 
that those values carry, here we are simply interested in describing the normative 
plan that the PMI promotes as a federally supported science policy initiative.
It is notable that in the 2016 PMI summit at the White House, President 
Obama’s remarks reiterated the centrality of those positive values in several ways. 
Two passages in particular spelled out the cultural, not just the scientific, promise 
of precision medicine. First, the President described the core message of the ini-
tiative as “empowering individuals to monitor and take a more active role in their 
own health” (emphasis added). Second, the President remarked about the ethics 
of data ownership, by pointing out that creating a large precision medicine cohort 
“requires, first of all, us understanding who owns the data. And I would like to 
think that if somebody does a test on me or my genes, that’s mine. But that’s not 
always how we define these issues” (White House 2016).
Data ownership is a hotly debated issue, likely to affect the development of 
precision medicine in the years to come. A number of stakeholders, including par-
ticipants, clinical institutions, sponsors, and researchers and their funders, all claim 
some kind of ownership over the data collected and generated in the course of 
research. Strong arguments on both sides critically bear on questions of empow-
erment and partnership (Terry and Terry 2011). Unsurprisingly, then, President 
Obama’s remark suggests the importance of attributing ownership to engaged 
participants who contribute samples and data.
This emphasis on the ethical value of public engagement, partnership, and em-
powerment is noteworthy in the legislative initiatives for personalized medicine. 
However, the emphasis on ethics is familiar in the broader context of discussions 
concerning biotechnology and genomic research in the last decade. In genomics, 
patients’ advocacy groups have long been championing a movement to shift data 
ownership and control to participants who actually contribute those data (Terry 
and Terry 2011). In particular, those movements are interested in promoting par-
ticipants’ sense of empowerment and participation by granting them a wide array 
of options concerning the selection of where their data should go, who should 
have access to the data, and how the data should be used. Allowing people to share 
their data, many patients’ advocates insist, will allow clinical trial data to circulate 
widely, thus boosting the odds of scientific discovery.
Appeals to these understandings have become a defining feature of precision 
medicine. Within this context, the idea of “patient engagement” has been de-
scribed as “the next blockbuster drug,” precisely because it offer patients the tools 
to become actively involved with their health (Chase 2016). Involving patients 
and the public more broadly in science and clinical matters has gained momen-
tum in discussions of regulating the increasingly complex challenges of risk man-
agement in biotechnology (Irwin 2006; Solomon, Gusmano, and Maschke 2016).
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Participant-centered governance initiatives have also gained widespread rec-
ognition with international research consortia that collect and analyze extensive 
datasets (Kaye et al. 2012). With large-scale biobanking research activities, partic-
ipants’ engagement as partners of research can now be considered a central com-
ponent of mainstream ethical frameworks (Blasimme and Vayena 2016).
Notably, these values are also being explicitly articulated in the private sector. 
In particular, the personal genomic industry has grown around a narrative of 
empowerment. Pioneering players in this sector, like 23andMe, have long been 
selling genomic testing to consumers based on the idea that consumers can be 
empowered to freely make choices about their health based on the test results, 
without invention from their physicians (Prainsack and Vayena 2013; Vayena 2014). 
As the NIH develops an infrastructure for precision medicine centered around 
a 1 million participant research cohort, 23andMe already possesses samples and 
SNPs data from 1.5 million customers, revealing the capacity of the private sector 
to shape the development of big data health research by leveraging both cultural 
and material resources.
Framing precision medicine with the core ethical values of public engagement, 
partnership, and empowerment aligns the model with prominent normative nar-
ratives characterizing genetics, genomics, and biobanking research. This ethical 
framework may have been a major driver in ensuring federal support for precision 
medicine. Despite widespread enthusiasm for the ethos of participation, however, 
the idea of empowerment has also attracted some pointed criticism. Eric Juengst 
and colleagues, for example, point out that while a rhetoric of empowerment is 
gaining ground in federal policy, it raises a risk of “a relocation of responsibility 
for health care away from social and political realms and onto the shoulders of the 
patients” themselves (Juengst, Flatt, and Settersten 2012, 36). Obviously, it is too 
early to know whether this risk will actually materialize as precision medicine 
moves forward. Nevertheless, we need to pay attention to how a driving norma-
tive ideal centered around empowerment might take shape in practice, and what 
its ethical tradeoffs might be.
Conclusion
The creation of a large-scale centralized cohort with millions of participants rep-
resents the visible material incarnation of precision medicine as a novel federally 
supported biomedical model. The initiative is also unusual with respect to how re-
search participants and patients involved in its development are to be considered, 
how they will be involved, and how they are to be treated. Precision medicine 
incorporates a central role for patients and research participants understood as 
“active partners in clinical research” (Collins and Varmus 2015). In part by taking 
ethical issues seriously, the initiative has received a remarkable level of institutional 
and political support.
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The launch of PMI shows how specific values can become embedded in the 
public articulation of biomedical programs. Careful examination of the process 
can clarify how innovations are granted or denied political recognition and sup-
port. Scientific progress and political usefulness alone are not sufficient to explain 
the success of precision medicine as a federally supported initiative. Weaving to-
gether the scientific and legislative antecedents of precision medicine illuminates 
how the mutual constitution of science and ethical values can generate political 
recognition for an innovative biomedical paradigm (Jasanoff 2005).
References
Bayer, R., and S. Galea. 2015. “Public Health in the Precision-Medicine Era.” N Engl J Med 
373 (6): 499–501. doi:10.1056/NEJMp1506241.
Biomarkers Definitions Working Group. 2001. “Biomarkers and Surrogate Endpoints: 
Preferred Definitions and Conceptual Framework.” Clin Pharmacol Ther 69 (3): 89–95. 
doi:10.1067/mcp.2001.113989.
Blasimme, A. and E. Vayena. 2016. “Becoming Partners, Retaining Autonomy: Ethical 
Considerations on the Development of Precision Medicine.” BMC Medical Ethics 17:67.
Chase, D. 2016. “Patient Engagement Is the Blockbuster Drug of the Century.” Forbes, 
Sept. 9. http://www.forbes.com/sites/davechase/2012/09/09/patient-engagement-is-
the-blockbuster-drug-of-the-century/.
Chin, L., J. N. Andersen, and P. A. Futreal. 2011. “Cancer Genomics: From Discovery Sci-
ence to Personalized Medicine.” Nat Med 17 (3): 297–303.
Christensen, C. M., J. H. Grossman, and J. Hwang. 2009. The Innovator’s Prescription: A 
Disruptive Solution for Health Care. New York: McGraw-Hill.
Collins, F. S., and H. Varmus. “A New Initiative on Precision Medicine.” N Engl J Med 37 
(9): 793–95.
Evans, W. E., and M. V. Relling. 1999. “Pharmacogenomics: Translating Functional Ge-
nomics into Rational Therapeutics.” Science 286 (5439): 487–91.
Evans, W. E., and M. V. Relling. 2004. “Moving Towards Individualized Medicine with 
Pharmacogenomics.” Nature 429: 464–68.
Flores, M., et al. 2013. “P4 Medicine: How Systems Medicine Will Transform the Health-
care Sector and Society.” Pers Med 10 (6): 565–76.
Gardiner, S. J., and E. J. Begg. 2006. “Pharmacogenetics, Drug-Metabolizing Enzymes, and 
Clinical Practice.” Pharmacol Rev 58 (3): 521–90.
Ginsburg, G. S., and J. J. McCarthy. 2001. “Personalized Medicine: Revolutionizing Drug 
Discovery and Patient Care.” Trends Biotechnol 19 (12): 491–96. doi:10.1016/S0167-
7799(01)01814-5.
Ginsburg, G. S., and H. F. Willard. 2009. “Genomic and Personalized Medicine: Founda-
tions and Applications.” Transl Res 154 (6): 277–87.
Gonzalez, F. J. 1988. “The Molecular Biology of Cytochrome P450s.” Pharmacol Rev 40 
(4): 243–88.
Hamburg, M. A., and F. S. Collins. 2010. “The Path to Personalized Medicine.” N Engl J 
Med 363 (4): 301–4.
“Tailored-to-You”
187spring 2016 • volume 59, number 2
Hawgood, S., et al. 2015. “Precision Medicine: Beyond the Inflection Point.” Sci Transl Med 
7 (300): 300ps17. doi:10.1126/scitranslmed.aaa9970.
Hood, L., and M. Flores. 2012. “A Personal View on Systems Medicine and the Emergence 
of Proactive P4 Medicine: Predictive, Preventive, Personalized and Participatory.” New 
Biotechnol 29 (6): 613–24.
Hood, L., and S. H. Friend. 2011. “Predictive, Personalized, Preventive, Participatory (P4) 
Cancer Medicine.” Nat Rev Clin Oncol 8 (3): 184–87.
Irwin, A. 2006. “The Politics of Talk Coming to Terms with the ‘New’ Scientific Gover-
nance.” Soc Stud Sci 36 (2): 299–320. doi:10.1177/0306312706053350.
Jasanoff, S. 2004. “Ordering Knowledge, Ordering Society.” In States of Knowledge: The 
Co-Production of Science and the Social Order, ed. S. Jasanoff, 13–45. London: Routledge.
Jones, D. S. 2013. “The Prospects of Personalized Medicine.” In Genetic Explanation: Sense 
and Nonsense, 147–70. Cambridge: Harvard University Press.
Juengst, E. T., M. A. Flatt, and R. A. Settersten. 2012. “Personalized Genomic Medicine and 
the Rhetoric of Empowerment.” Hastings Cent Rep 42 (5): 34–40.
Kaye, J., et al. 2012. “From Patients to Partners: Participant-Centric Initiatives in Biomed-
ical Research.” Nat Rev Genet 13 (5): 371–76.
Kitano, H. 2002. “Systems Biology: A Brief Overview.” Science 295 (5560): 1662–64.
Meyer, U. A. 2000. “Pharmacogenetics and Adverse Drug Reactions.” Lancet 356 (9242): 
1667–71.
National Research Council. (2011). Committee on A Framework for Developing a New 
Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Bio-
medical Research and a New Taxonomy of Disease. Washington, DC: National Academies 
Press.
Nicholson, J. K. 2006. “Global Systems Biology, Personalized Medicine and Molecular 
Epidemiology.” Mol Syst Biol 2 (1). doi:10.1038/msb4100095.
Prainsack, B., and E. Vayena. 2013. “Beyond the Clinic: ‘Direct-to-Consumer’ Genomic 
Profiling Services and Pharmacogenomics.” Pharmacogenomics 14 (4): 403–12.
Precision Medicine Initiative (PMI) Working Group. 2015. The Precision Medicine Cohort 
Program: Building a Research Foundation for 21st Century Medicine. NIH. http://acd.
od.nih.gov/reports/DRAFT-PMI-WG-Report-9-11-2015-508.pdf.
Roses, A. D. 2000. “Pharmacogenetics and the Practice of Medicine.” Nature 405 (6788): 
857–65.
Roses, A. D. 2004. “Pharmacogenetics and Drug Development: The Path to Safer and 
More Effective Drugs.” Nat Rev Genet 5 (9): 645–56.
Solomon, M. Z., M. K. Gusmano, and K. J. Maschke. 2016. “The Ethical Imperative and 
Moral Challenges of Engaging Patients and the Public with Evidence.” Health Aff (Mill-
wood) 35 (4): 583–89. doi:10.1377/hlthaff.2015.1392.
Steele, F. R. 2009. “Personalized Medicine: Something Old, Something New.” Pers Med 6 
(1): 1–5. 
Terry, S. F., and P. F. Terry. 2011. “Power to the People: Participant Ownership of Clinical 
Trial Data.” Sci Transl Med 3 (69): 69cm3.
U.S. Food and Drug Administration (FDA). 2016. Table of Pharmacogenomic Biomark-
ers in Drug Labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/
Pharmacogenetics/ucm083378.htm.
Alessandro Blasimme and Effy Vayena
188 Perspectives in Biology and Medicine
Vayena, E. 2014. “Direct-to-Consumer Genomics on the Scales of Autonomy.” J Med Eth-
ics 41 (4): 310–14. doi:10.1136/medethics-2014-102026.
Weston, A. D., and L. Hood. 2004. “Systems Biology, Proteomics, and the Future of Health 
Care: Toward Predictive, Preventative, and Personalized Medicine.” J Proteome Res 3 (2): 
179–96.
Whirl-Carrillo, M., et al. 2012. “Pharmacogenomics Knowledge for Personalized Medi-
cine.” Clin Pharmacol Ther 92 (4): 414–17. doi:10.1038/clpt.2012.96.
White House. 2015a. Fact Sheet: President Obama’s Precision Medicine Initiative. 
https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-presi-
dent-obama-s-precision-medicine-initiative.
White House. 2015b. Privacy and Trust Principles for the President’s Precision Medicine 
Initiative. https://www.whitehouse.gov/sites/default/files/microsites/finalpmipriva-
cyandtrustprinciples.pdf.
White House. 2015c. Remarks by the President on Precision Medicine. https://www.
whitehouse.gov/the-press-office/2015/01/30/remarks-president-precision-medicine.
White House. 2016. Remarks of the President in Precision Medicine Panel Discussion. 
2016. https://www.whitehouse.gov/the-press-office/2016/02/25/remarks-president- 
precision-medicine-panel-discussion.
